Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Evolution of kinase polypharmacology across HSP90 drug discovery

View ORCID ProfileAlbert A. Antolin, View ORCID ProfilePaul A. Clarke, Ian Collins, View ORCID ProfilePaul Workman, View ORCID ProfileBissan Al-Lazikani
doi: https://doi.org/10.1101/2020.09.09.288936
Albert A. Antolin
1Department of Data Science, The Institute of Cancer Research, London, SM2 5NG, UK
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Albert A. Antolin
  • For correspondence: Albert.Antolin@icr.ac.uk Paul.Workman@icr.ac.uk Bissan.Al-Lazikani@icr.ac.uk
Paul A. Clarke
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul A. Clarke
Ian Collins
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Workman
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paul Workman
  • For correspondence: Albert.Antolin@icr.ac.uk Paul.Workman@icr.ac.uk Bissan.Al-Lazikani@icr.ac.uk
Bissan Al-Lazikani
1Department of Data Science, The Institute of Cancer Research, London, SM2 5NG, UK
2Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Bissan Al-Lazikani
  • For correspondence: Albert.Antolin@icr.ac.uk Paul.Workman@icr.ac.uk Bissan.Al-Lazikani@icr.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

Abstract

Most small molecules interact with several target proteins but this polypharmacology is seldom comprehensively investigated or explicitly exploited during drug discovery. Here, we use computational and experimental methods to systematically characterize the kinase cross-pharmacology of representative HSP90 inhibitors. We demonstrate that the resorcinol clinical candidates ganetespib and, to a lesser extent, luminespib, display unique off-target kinase pharmacology as compared to other HSP90 inhibitors. We also demonstrate that polypharmacology evolved during the optimisation to discover luminespib and that the hit, leads and clinical candidate all have different polypharmacological profiles. We conclude that the submicromolar target inhibition of protein kinases by ganetespib may have potential clinical significance and we recommend the computational and experimental characterization of polypharmacology earlier in drug discovery projects to unlock new multi-target drug design opportunities.

Competing Interest Statement

A.A.A., P.A.C., I.C. P.W. and B.A.-L. are/were employees of The Institute of Cancer Research (ICR), which has a commercial interest in a range of drug targets, including HSP90 and protein kinases. P.W. and I.C. were involved in the discovery of luminespib which was funded by Vernalis and Cancer Research UK. The ICR operates a Rewards to Inventors scheme whereby employees of the ICR may receive financial benefit following commercial licensing of a project. P.W. is a consultant/scientific advisory board member for Nextech Invest Ltd, Storm Therapeutics, Astex Pharmaceuticals, Black Diamond and CV6 and holds stock in Chroma Therapeutics, NextInvest, Black Diamond and Storm Therapeutics; he is also a Non-Executive Director of Storm Therapeutics and the Royal Marsden NHS Trust and a Director of the non-profit Chemical Probes Portal. B.A.-L. is/was a consultant/ scientific advisory board member for GSK, Open Targets, Astex Pharmaceuticals, Astellas Pharma and is an ex-employee of Inpharmatica Ltd. A.A.A., B.A.-L. and P.W. have been instrumental in the creation/development of canSAR and Probe Miner. B.A.-L was instrumental in the creation of ChEMBL. I.C. is/was a consultant to Epidarex LLP, AdoRx Therapeutics and Enterprise Therapeutics, and is a Director of the non-profit Chemical Probes Portal. I.C. has received research funding from Astex, Merck KGaA, Janssen Biopharma, Monte Rosa Therapeutics and Sixth Element Capital/CRT Pioneer Fund. I.C. holds stock in Monte Rosa Therapeutics AG and is a former employee of Merck Sharp & Dohme.

Footnotes

  • ↵3 Lead contact:

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted September 10, 2020.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Evolution of kinase polypharmacology across HSP90 drug discovery
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Evolution of kinase polypharmacology across HSP90 drug discovery
Albert A. Antolin, Paul A. Clarke, Ian Collins, Paul Workman, Bissan Al-Lazikani
bioRxiv 2020.09.09.288936; doi: https://doi.org/10.1101/2020.09.09.288936
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Evolution of kinase polypharmacology across HSP90 drug discovery
Albert A. Antolin, Paul A. Clarke, Ian Collins, Paul Workman, Bissan Al-Lazikani
bioRxiv 2020.09.09.288936; doi: https://doi.org/10.1101/2020.09.09.288936

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Pharmacology and Toxicology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4121)
  • Biochemistry (8830)
  • Bioengineering (6535)
  • Bioinformatics (23492)
  • Biophysics (11817)
  • Cancer Biology (9233)
  • Cell Biology (13350)
  • Clinical Trials (138)
  • Developmental Biology (7452)
  • Ecology (11430)
  • Epidemiology (2066)
  • Evolutionary Biology (15181)
  • Genetics (10457)
  • Genomics (14057)
  • Immunology (9192)
  • Microbiology (22220)
  • Molecular Biology (8832)
  • Neuroscience (47666)
  • Paleontology (352)
  • Pathology (1432)
  • Pharmacology and Toxicology (2493)
  • Physiology (3741)
  • Plant Biology (8097)
  • Scientific Communication and Education (1438)
  • Synthetic Biology (2226)
  • Systems Biology (6046)
  • Zoology (1258)